Podcast: Akeso's Xia Looks Beyond Summit Deal To Independent Global Development, Sales

Last December, China's Akeso struck a major agreement worth up to $5bn with Summit Therapeutics, which set a new record in terms of total deal value for a single asset in the Chinese biopharma sector. Akeso founder and CEO Michelle Xia is now planning to pursue a more independent path in taking the firm global.

Summit
Akeso aiming for independent globalization beyond its deal with Summit Therapeutics • Source: Shutterstock

After striking a licensing deal valued at up to $5bn for a bispecific antibody with US biotech Summit Therapeutics plc in December, Chinese bioventure Akeso Inc.’s founder, chairwoman and CEO Michelle Xia shared her thoughts about the transaction and beyond in wide-ranging audio interview with Scrip.

With extensive international industry experience at companies including Bayer AG and PDL BioPharma, Inc. in the US, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia